Abstract:Recent studies connect the FAK and Wnt/β-catenin signaling pathways, both which promote cancer when aberrantly activated in mammalian cells. Over-stimulation of either Wnt/β-catenin or FAK activities was independently shown to promote numerous types of human cancers, including colon, breast, prostate and ovary. Observations in different model systems suggest a complex and dynamic cross-talk between these two pathways. During early vertebrate development, FAK protein is required for the proper regulation of Wnt/β- catenin signaling that controls pattern formation in the developing nervous system. In Xenopus laevis embryos, FAK protein depletion eliminated Wnt3a gene expression in the neural plate. In mouse osteoclast cells, mechanical stimulation through FAK activation stabilized β-catenin protein to promote its nuclear translocation. In contrast, in the mouse intestine, FAK activity was induced downstream of Wnt to promote intestinal regeneration and was also essential for tumorigenesis in an APC deletion model of colorectal cancer. Adding to this complexity, in human cell lines, FAK induced a context-dependent modulation of Wnt signaling to activate target-gene expression. Other diseases are also associated with FAK and Wnt pathway over-activation. Increased FAK and Wnt pathway activities were independently implicated in idiopathic pulmonary fibrosis (IPF), a lung disease of unknown etiology. Revealing the FAK-Wnt connection in IPF could provide a better understanding of disease pathology. There appear to be multiple interactions between the Wnt/β-catenin and FAK signaling pathways in different cell types and organisms. Mutual FAK-Wnt pathway regulation could be a general phenomenon, having many still undetermined roles in either normal physiological or disease processes.

Unlocking the Wnt pathway: Therapeutic potential of selective targeting FZD7 in cancer

Frizzled receptors (FZDs) in Wnt signaling: potential therapeutic targets for human cancers

Frizzled7 as an emerging target for cancer therapy

Structure-guided Design Fine-Tunes Pharmacokinetics, Tolerability, and Antitumor Profile of Multispecific Frizzled Antibodies

Progress in the Development of Modulators Targeting Frizzleds

The Wnt signaling pathway: a potential therapeutic target against cancer

The Crosstalk between FAK and Wnt Signaling Pathways in Cancer and Its Therapeutic Implication

Inhibition of nuclear Wnt signalling: challenges of an elusive target for cancer therapy

Targeting the Wnt/β-catenin signaling pathway in cancer

Modulating the wnt signaling pathway with small molecules

Pharmacological interventions in the Wnt pathway: inhibition of Wnt secretion versus disrupting the protein-protein interfaces of nuclear factors

Wnt/β-catenin signaling in cancers and targeted therapies

Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex

The Wnt signaling pathway in tumorigenesis, pharmacological targets, and drug development for cancer therapy

Structure-Based Ligand Discovery Targeting the Transmembrane Domain of Frizzled Receptor FZD7

Blocking the WNT/β-catenin pathway in cancer treatment:pharmacological targets and drug therapeutic potential

FZD7 has a critical role in cell proliferation in triple negative breast cancer

FAK and WNT signaling: the meeting of two pathways in cancer and development

Wnt signaling in human and mouse breast cancer: Focusing on Wnt ligands, receptors and antagonists

Targeted inhibition of Wnt signaling with a bacterial toxin fragment suppresses breast cancer tumor-initiating/chemo-resistant cells

Developing and characterization of single chain variable fragment (scFv) antibody against frizzled 7 (Fzd7) receptor